Xiuning Le MD, PhDAssistant Professor, University of Texas M.D. Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, Houston, TX
As an Assistant Professor in the Thoracic/Head and Neck department, Dr. Le has a clinical and research expertise in treating oncogene-driven non-small cell lung cancer.
Dr. Le earned her medical degree from the Peking Union Medical College (PUMC) and Ph.D. degree in Biological and Biomedical Sciences at Harvard Medical School (HMS) in Boston. She completed her internship and residency at the University of Massachusetts Medical Center in Worcester, MA. She then completed a hematology/oncology fellowship at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School. During the research fellowship at Dana-Farber Cancer Institute (DFCI), she focused on genomics approaches to understand cancer resistance. Board certified in both internal medicine and medical oncology, Dr. Le specializes in thoracic, head, and neck oncology.
Professional highlights and publications/awards
Dr. Le’s research focuses on improving targeted therapeutics for lung cancer, bringing new actionable targets to lung and head/neck cancer, developing novel biomarkers in precision oncology. She and her colleagues have published high-impact journal articles, including New England Journal of Medicine, Nature, Journal of Clinical Oncology, Cancer Discovery. The clinical trials led by Dr. Le has resulted in FDA approval of novel targeted therapy in lung cancer.
Dr. Le has received numerous awards and grants, including ASCO Young Investigator Award and Career Development Award, Paul Calabresi Award, SU2C-TVF Convergence Scholar, Claudia Adams Barr for Innovative Cancer Research Award, Stiefel Foundation, Rexanna Foundation, Khalifa Foundation and other awards.
Conflict of interest
Dr. Le receives consulting/advisory fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim, Hengrui Therapeutics, Janssen, and Abbvie, and Research Funding from Eli Lilly, EMD Serono, Regeneron, and Boehringer Ingelheim.